WO2000074703A3 - Therapeutikum mit einem botulinum-neurotoxin - Google Patents

Therapeutikum mit einem botulinum-neurotoxin Download PDF

Info

Publication number
WO2000074703A3
WO2000074703A3 PCT/DE2000/001777 DE0001777W WO0074703A3 WO 2000074703 A3 WO2000074703 A3 WO 2000074703A3 DE 0001777 W DE0001777 W DE 0001777W WO 0074703 A3 WO0074703 A3 WO 0074703A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurotoxins
therapeutic agent
botulinum neurotoxin
botulinum
neurotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2000/001777
Other languages
English (en)
French (fr)
Other versions
WO2000074703B1 (de
WO2000074703A2 (de
Inventor
Hans Bigalke
Juergen Frevert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotecon Therapeutics GmbH
Original Assignee
Biotecon GmbH Gesellschaft fuer Biotechnologische Entwicklung und Consultimg mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7910318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000074703(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SI200030341T priority Critical patent/SI1185291T1/xx
Priority to PL352468A priority patent/PL198958B1/pl
Priority to CA002376193A priority patent/CA2376193C/en
Priority to DE10081516T priority patent/DE10081516D2/de
Priority to JP2001501237A priority patent/JP2003505343A/ja
Priority to DE50005208T priority patent/DE50005208D1/de
Priority to AT00943666T priority patent/ATE258803T1/de
Priority to US10/018,373 priority patent/US7964199B1/en
Priority to AU58047/00A priority patent/AU774590B2/en
Priority to DK00943666T priority patent/DK1185291T3/da
Priority to MXPA01012540A priority patent/MXPA01012540A/es
Application filed by Biotecon GmbH Gesellschaft fuer Biotechnologische Entwicklung und Consultimg mbH filed Critical Biotecon GmbH Gesellschaft fuer Biotechnologische Entwicklung und Consultimg mbH
Priority to HK02108892.0A priority patent/HK1047403B/xx
Priority to EP00943666A priority patent/EP1185291B2/de
Priority to UA2002010181A priority patent/UA72253C2/uk
Priority to EA200200017A priority patent/EA004202B1/ru
Priority to IL14697400A priority patent/IL146974A0/xx
Publication of WO2000074703A2 publication Critical patent/WO2000074703A2/de
Publication of WO2000074703A3 publication Critical patent/WO2000074703A3/de
Publication of WO2000074703B1 publication Critical patent/WO2000074703B1/de
Priority to IL146974A priority patent/IL146974A/en
Priority to NO20015964A priority patent/NO20015964L/no
Anticipated expiration legal-status Critical
Priority to US13/068,439 priority patent/US20110217287A1/en
Priority to US13/303,973 priority patent/US8398998B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Pharmazeutische Zubereitung, enthaltend eines der Botulinum-Neurotoxine von Clostridium botulinum der Typen A, B, C, D, E, F oder G oder ein Gemisch von zwei oder mehr dieser Neurotoxine, dadurch gekennzeichnet, dass das Neurotoxin bzw. das Gemisch der Neurotoxine frei ist von den komplexierenden Proteinen, die natürlicherweise zusammen mit den Neurotoxinen die Botulinum-Neurotoxin-Komplexe bilden.
PCT/DE2000/001777 1999-06-07 2000-05-26 Therapeutikum mit einem botulinum-neurotoxin Ceased WO2000074703A2 (de)

Priority Applications (20)

Application Number Priority Date Filing Date Title
UA2002010181A UA72253C2 (uk) 1999-06-07 2000-05-26 Застосування ботулінічного нейротоксину, вільного від комплексоутворюючих білків, для одержання фармацевтичного засобу
HK02108892.0A HK1047403B (en) 1999-06-07 2000-05-26 Therapeutic agent comprising a botulinum neurotoxin
CA002376193A CA2376193C (en) 1999-06-07 2000-05-26 Therapeutic agent comprising a botulinum neurotoxin
DE10081516T DE10081516D2 (de) 1999-06-07 2000-05-26 Therapeutikum mit einem Botulinum-Neurotoxin
JP2001501237A JP2003505343A (ja) 1999-06-07 2000-05-26 ボツリヌス神経毒を含む治療薬
DE50005208T DE50005208D1 (de) 1999-06-07 2000-05-26 Therapeutikum mit einem botulinum-neurotoxin
AT00943666T ATE258803T1 (de) 1999-06-07 2000-05-26 Therapeutikum mit einem botulinum-neurotoxin
US10/018,373 US7964199B1 (en) 1999-06-07 2000-05-26 Therapeutic composition comprising a botulinum neurotoxin
AU58047/00A AU774590B2 (en) 1999-06-07 2000-05-26 Therapeutic agent comprising a botulinum neurotoxin
PL352468A PL198958B1 (pl) 1999-06-07 2000-05-26 Zastosowanie neurotoksyny botulinowej z Clostridium botulinum
MXPA01012540A MXPA01012540A (es) 1999-06-07 2000-05-26 Agente terapeutico que contiene una neurotoxina de botulismo.
SI200030341T SI1185291T1 (en) 1999-06-07 2000-05-26 Therapeutic agent comprising a botulinum neurotoxin
EP00943666A EP1185291B2 (de) 1999-06-07 2000-05-26 Therapeutikum mit einem botulinum-neurotoxin
IL14697400A IL146974A0 (en) 1999-06-07 2000-05-26 Therapeutic composition comprising a botulinum neurotoxin
DK00943666T DK1185291T3 (da) 1999-06-07 2000-05-26 Terapeutisk middel til et botulinum-neurotoksin
EA200200017A EA004202B1 (ru) 1999-06-07 2000-05-26 Терапевтическое средство с ботулиническим нейротоксином
NO20015964A NO20015964L (no) 1999-06-07 2001-12-06 Terapeutisk middel omfattende et botulinum-neurotoksin
IL146974A IL146974A (en) 1999-06-07 2001-12-06 Use of a botulinum neurotoxin for the manufacture of a medicament
US13/068,439 US20110217287A1 (en) 1999-06-07 2011-05-11 Therapeutic composition comprising a botulinum neurotoxin
US13/303,973 US8398998B2 (en) 1999-06-07 2011-11-23 Therapeutic composition comprising a botulinum neurotoxin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19925739.6 1999-06-07
DE19925739A DE19925739A1 (de) 1999-06-07 1999-06-07 Therapeutikum mit einem Botulinum-Neurotoxin

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/018,373 A-371-Of-International US7964199B1 (en) 1999-06-07 2000-05-26 Therapeutic composition comprising a botulinum neurotoxin
US13/068,439 Continuation US20110217287A1 (en) 1999-06-07 2011-05-11 Therapeutic composition comprising a botulinum neurotoxin

Publications (3)

Publication Number Publication Date
WO2000074703A2 WO2000074703A2 (de) 2000-12-14
WO2000074703A3 true WO2000074703A3 (de) 2001-04-26
WO2000074703B1 WO2000074703B1 (de) 2001-06-07

Family

ID=7910318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2000/001777 Ceased WO2000074703A2 (de) 1999-06-07 2000-05-26 Therapeutikum mit einem botulinum-neurotoxin

Country Status (26)

Country Link
US (3) US7964199B1 (de)
EP (1) EP1185291B2 (de)
JP (2) JP2003505343A (de)
KR (1) KR100466407B1 (de)
CN (2) CN101062009A (de)
AR (1) AR024306A1 (de)
AT (1) ATE258803T1 (de)
AU (1) AU774590B2 (de)
CA (1) CA2376193C (de)
CO (1) CO5170431A1 (de)
CZ (1) CZ20014351A3 (de)
DE (3) DE19925739A1 (de)
DK (1) DK1185291T3 (de)
EA (1) EA004202B1 (de)
ES (1) ES2215056T5 (de)
GE (1) GEP20043200B (de)
HU (1) HUP0201530A3 (de)
IL (2) IL146974A0 (de)
MX (1) MXPA01012540A (de)
NO (1) NO20015964L (de)
PL (1) PL198958B1 (de)
PT (1) PT1185291E (de)
TW (1) TWI251492B (de)
UA (1) UA72253C2 (de)
WO (1) WO2000074703A2 (de)
ZA (1) ZA200110074B (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
WO2003082315A1 (fr) * 2002-03-29 2003-10-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Remede contre l'hypermyotonie
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7288259B2 (en) * 2002-08-19 2007-10-30 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
ES2381091T3 (es) * 2003-03-06 2012-05-23 Botulinum Toxin Research Associates, Inc. Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
WO2004112821A1 (ja) * 2003-06-20 2004-12-29 Santen Pharmaceutical Co., Ltd. 筋緊張亢進性疾患の治療剤
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
CN1946431B (zh) 2004-03-03 2011-12-07 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
BRPI0513850A (pt) * 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
AU2005288758A1 (en) * 2004-09-27 2006-04-06 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins for use in tissue healing
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2006096163A1 (en) * 2005-03-03 2006-09-14 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
HRP20090382T1 (hr) * 2005-06-17 2009-09-30 Merz Pharma Gmbh & Co.Kgaa Uređaj i postupak za proizvodnju biološko aktivnih spojeva fermentacijom
NZ568216A (en) 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
EP1834962A1 (de) * 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
EP2048156A1 (de) * 2007-10-12 2009-04-15 Merz Pharma GmbH & Co.KGaA Prozess zur Bereitstellung eines temperaturstabilen Muskelrelaxans auf der Basis der neurotoxischen Komponente von Botulintoxin
CA2686642A1 (en) * 2007-06-01 2008-12-04 Merz Pharma Gmbh & Co. Kgaa Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
DE102007038015A1 (de) * 2007-08-10 2009-02-19 Hefter, Harald, Prof. Dr. med. Dr. rer. nat. Verwendung eines Neurotoxins
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
EP2072039A1 (de) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Verwendung eines neurotoxischen Bestandteils des Clostridium-botulinum-Toxinkomplexes zur Verringerung oder Verhütung von Nebenwirkungen
EP2072057A1 (de) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Frühe Verabreichung von Botulinumtoxin bei der Behandlung von zerebrovaskulären Ereignissen und Rückenmarksverletzungen
EP2246426A4 (de) * 2008-01-29 2011-08-10 Inst Antibodies Co Ltd Zusammensetzung zur neutralisierung von botulinustoxin typ-a und menschlicher antikörper gegen botulinustoxin typ-a
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
PL2271670T3 (pl) * 2008-03-14 2015-05-29 Allergan Inc Testy aktywności serotypu A toksyny botulinowej oparte na immunologii
WO2009123174A1 (ja) * 2008-03-31 2009-10-08 財団法人化学及血清療法研究所 A2型ボツリヌス神経毒素製剤
EP2337790B1 (de) 2008-08-29 2016-07-13 Merz Pharma GmbH & Co. KGaA Clostridien-neurotoxine mit veraenderter persistenz
ES2426667T3 (es) 2008-09-09 2013-10-24 Susanne Grafe Toxina botulínica para introducir infertilidad temporal en un vertebrado (por ejemplo, un ser humano)
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
EP2248518B1 (de) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulierung zur Stabilisierung von Proteinen, Peptiden und deren Mischungen.
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
JP2011074025A (ja) * 2009-09-30 2011-04-14 Chemo-Sero-Therapeutic Research Inst ボツリヌス毒素の精製方法
PH12012500549A1 (en) 2009-10-21 2017-08-23 Revance Therapeutics Inc Methods and systems for purifying non-complexed botulinum neurotoxin
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
JP5990176B2 (ja) 2010-10-12 2016-09-07 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
EP2724725B1 (de) * 2011-06-27 2016-09-07 Sang Duck Kim Pharmazeutische zusammensetzung zur verwendung in der behandlung von narben auf der haut
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
KR102272580B1 (ko) * 2013-07-30 2021-07-05 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US20180140685A1 (en) * 2015-04-24 2018-05-24 Consiglio Nazionale Delle Ricerche A new therapeutic use of the botulinum neurotoxin serotype a
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
KR102463881B1 (ko) 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
JP7604222B2 (ja) 2017-03-22 2024-12-23 ボンチ インコーポレイテッド 治療用のボツリヌス神経毒素
BR112019016585A2 (pt) 2017-03-24 2020-03-31 Merz Pharma Gmbh & Co. Kgaa Uso melhorado da neurotoxina botulínica no tratamento da sialorreia
EP3843777A4 (de) 2018-08-28 2022-05-04 Ira Sanders Therapeutika für die haut
EP3860640A1 (de) 2018-10-02 2021-08-11 Merz Pharma GmbH & Co. KGaA Neuartige verwendungen von botulinumneurotoxin zur behandlung von lipoödem
MX2021009922A (es) 2019-02-21 2021-09-14 Merz Pharma Gmbh & Co Kgaa Usos novedosos de neurotoxina botulinica para el tratamiento del temblor.
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume
KR102724651B1 (ko) * 2021-07-08 2024-11-01 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
TW202400122A (zh) 2022-02-28 2024-01-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素用於降低皮膚毛孔尺寸及／或皮脂產生之用途、以及降低皮膚毛孔尺寸及／或皮脂產生的方法
EP4626556A1 (de) 2022-11-28 2025-10-08 Merz Pharma GmbH & Co. KGaA Behandlung von hochkonzentriertem botulinumtoxin zur halsverjüngung
AU2023400491A1 (en) 2022-11-28 2025-04-10 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin injection in platysma for lower face and neck rejuvenation
WO2024194181A1 (en) 2023-03-20 2024-09-26 Merz Therapeutics GmbH Nh3 scavenger for use in the treatment of mobility disability in a post-stroke patient
WO2024240868A1 (en) 2023-05-23 2024-11-28 Merz Therapeutics GmbH Botulinum toxin for treating peripheral neuropathic pain
KR20260035809A (ko) 2023-07-12 2026-03-13 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소에 의한 과색소침착 상태의 치료
WO2025228877A1 (en) 2024-04-29 2025-11-06 Merz Therapeutics GmbH Botulinum toxin for the preventive treatment of migraine
WO2026021713A1 (en) 2024-07-23 2026-01-29 Merz Therapeutics GmbH Uses of magnetic nerve stimulation associated with botulinum neurotoxin administration

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028923A1 (en) * 1993-06-10 1994-12-22 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
WO1996039167A1 (en) * 1995-06-06 1996-12-12 Pearce L Bruce Improved compositions and methods for chemodenervation using neurotoxins
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236692T3 (es) 1993-05-14 2005-07-16 Stephen S Arnon Un metodo para prevenir los efectos secundarios y la insensibilidad a los usos terapeuticos de toxinas.
ES2332905T3 (es) 1993-12-28 2010-02-15 Allergan, Inc. Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
PT1086702E (pt) 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
WO1996005222A1 (en) 1994-08-08 1996-02-22 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
EP1011695B2 (de) * 1997-07-15 2009-11-04 The Regents of the University of Colorado Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
BRPI1014253A2 (pt) * 2009-07-02 2016-04-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028923A1 (en) * 1993-06-10 1994-12-22 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
WO1996039167A1 (en) * 1995-06-06 1996-12-12 Pearce L Bruce Improved compositions and methods for chemodenervation using neurotoxins
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EDITORIAL: "botulinum toxin", THE LANCET, vol. 340, no. 19/26, December 1992 (1992-12-01), pages 1508 - 1509, XP002158435 *
GOESCHEL HILKE ET AL: "Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies-therapeutic consequences.", EXPERIMENTAL NEUROLOGY, vol. 147, no. 1, 1997, pages 96 - 102, XP002158434, ISSN: 0014-4886 *
KEEN M ET AL: "Botulinum Toxin A for Hyperkinetic Facial Lines: Results of a Double-Blind, Placebo-Controlled Study", PLASTIC AND RECONSTRUCTIVE SURGERY, vol. 94, no. 1, July 1994 (1994-07-01), pages 94 - 99, XP000982177 *
NAUMANN M ET AL: "Depletion of neutralising antibodies resensitizes a secondary non-responder to botulinum A neurotoxin.", JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, vol. 65, no. 6, December 1998 (1998-12-01), pages 924 - 927, XP000979025, ISSN: 0022-3050 *

Also Published As

Publication number Publication date
DE19925739A1 (de) 2000-12-21
HK1047403A1 (zh) 2003-02-21
ZA200110074B (en) 2003-03-06
EP1185291B2 (de) 2010-10-27
DE10081516D2 (de) 2001-09-13
HUP0201530A2 (en) 2002-09-28
PT1185291E (pt) 2004-06-30
EP1185291B1 (de) 2004-02-04
HUP0201530A3 (en) 2002-10-28
IL146974A0 (en) 2002-08-14
CO5170431A1 (es) 2002-06-27
CN1354670A (zh) 2002-06-19
IL146974A (en) 2007-05-15
EA004202B1 (ru) 2004-02-26
PL198958B1 (pl) 2008-08-29
TWI251492B (en) 2006-03-21
JP2003505343A (ja) 2003-02-12
CA2376193C (en) 2008-09-16
UA72253C2 (uk) 2005-02-15
WO2000074703B1 (de) 2001-06-07
PL352468A1 (en) 2003-08-25
DE50005208D1 (de) 2004-03-11
AR024306A1 (es) 2002-09-25
US8398998B2 (en) 2013-03-19
NO20015964D0 (no) 2001-12-06
US7964199B1 (en) 2011-06-21
CZ20014351A3 (cs) 2002-06-12
CA2376193A1 (en) 2000-12-14
WO2000074703A2 (de) 2000-12-14
MXPA01012540A (es) 2004-09-27
JP2007238627A (ja) 2007-09-20
AU774590B2 (en) 2004-07-01
EA200200017A1 (ru) 2002-06-27
NO20015964L (no) 2002-01-30
AU5804700A (en) 2000-12-28
US20110217287A1 (en) 2011-09-08
CN100389820C (zh) 2008-05-28
GEP20043200B (en) 2004-03-25
EP1185291A2 (de) 2002-03-13
KR20020008214A (ko) 2002-01-29
KR100466407B1 (ko) 2005-01-27
ES2215056T5 (es) 2011-03-15
CN101062009A (zh) 2007-10-31
ATE258803T1 (de) 2004-02-15
US20120088732A1 (en) 2012-04-12
DK1185291T3 (da) 2004-04-05
ES2215056T3 (es) 2004-10-01

Similar Documents

Publication Publication Date Title
WO2000074703A3 (de) Therapeutikum mit einem botulinum-neurotoxin
EP0911039A3 (de) Wirkstoff-Harzkomplexe stabilisiert mit Chelatbildner
WO2006020208A3 (en) Therapeutic composition whit a botulinum neurotoxin
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
AU1453200A (en) Cyclic peptide ligands that target urokinase plasminogen activator receptor, their pharmaceutical compositions and use
EP1366771A3 (de) Verwendung vom neurotoxischem Komponent von Botulinum toxin als Medikament
AU1482102A (en) Complexes of phosphate derivatives
IL140338A0 (en) Amino acid derivatives which inhibit dipeptidyl peptidase iv and pharmaceutical compositions containing the same
AU7261994A (en) Hydrazino-type radionuclide chelators having an n3s configuration
ATE252601T1 (de) Lang wirkende insulinotrope peptide
WO1998027959A3 (de) Neue wässerige arzneimittelzubereitungen zur erzeugung treibgasfreier aerosole
ATE221386T1 (de) Stabilisierte flüssige arzneizubereitungen enthaltend botulinum toxin
IL160641A0 (en) Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
WO2000023094A3 (en) Methods of inhibiting platelet activation and recruitment
AU1378395A (en) Metal chelators
WO1998008505A8 (en) Pharmaceutical compounds
WO2001072264A3 (de) Pro-liposomal verkapselte zubereitungen (iv)
WO1999064587A8 (fr) Polypeptides possedant une activite de type beta-secretase
WO2001013933A3 (en) Agents for the enhanced oxygen delivery in mammals
WO2003053180A3 (de) Wirkstoffhaltige unterwäsche
WO2001034641A8 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
WO1996041627A3 (en) Iron compounds, compositions, methods of making the same and uses thereof
WO2004056347A3 (en) Pharmaceutical compositions comprising insulin and legends of insulin hexamer
WO2000034447A3 (en) Human ubiquitin ligase e3 for the modulation of nf-kappa b
WO2003057831A3 (en) Dtat fusion toxin

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808641.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
REF Corresponds to

Ref document number: 10081516

Country of ref document: DE

Date of ref document: 20010913

WWE Wipo information: entry into national phase

Ref document number: 10081516

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: PV2001-4351

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020017015668

Country of ref document: KR

Ref document number: PA/a/2001/012540

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2376193

Country of ref document: CA

Ref document number: 2376193

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2001 501237

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/10074

Country of ref document: ZA

Ref document number: 10018373

Country of ref document: US

Ref document number: 200110074

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 58047/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000943666

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200200017

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020017015668

Country of ref document: KR

WD Withdrawal of designations after international publication

Free format text: DE

WWP Wipo information: published in national office

Ref document number: 2000943666

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2001-4351

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2000943666

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1020017015668

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 58047/00

Country of ref document: AU